Kornimate/medical-research-clean huggingface dataset:
house calls and peer mentorship

Conditions: Chronic Kidney Disease; End-Stage Renal Disease

Summary: live donor kidney transplantation (ldkt) offers the most optimal survival and quality of life benefit for those with late-stage chronic kidney disease. however, minorities, especially blacks, are much less likely to receive ldkt than whites. given the shortage of deceased donor organs, interventions expanding access to ldkt are needed, particularly for minority patients. house calls (hc), an educational intervention developed by this study's pi has been shown to be an effective program for raising rates of live donation, especially for black patients. while the hc program has shown outstanding results, participant feedback suggested that follow-up may provide even more benefits. previous research suggests that peer mentorship (pm) from former or current patients with esrd may be effective in raising rates of living donation. as such, peer mentorship programs may act as an effective follow-up for hc participants. this study will examine the impact of the hc intervention combined with the peer mentorship program of the national kidney foundation on rates of live donor kidney transplantation.


Eligibility criteria:
inclusion criteria: * black race (including possible cape verdean, haitian, dominican) * ≥18 yrs old * english speaking * meets eligibility criteria for kidney transplant evaluation * ability to provide informed consent * resides within 1.5 hr drive of hc educator exclusion criteria: * temporarily unavailable (tu) on the waiting list and tu is likely to exceed 6 months based on judgement of kidney transplant team * awaiting combined kidney-liver transplantation * awaiting simultaneous pancreas-kidney transplantation * participation in another study to increase the likelihood of ldkt * prior participation in a transplant hc * prior or current participation in the nkf pm program

Keywords: live donor kidney transplantation ldkt disparity african american education patient support
exercise habits and preferences of community dwelling older adults with chronic pain

Conditions: Chronic Pain

Summary: objective: * to explore the exercise habits and preferences of community dwelling older adults with chronic pain * to explore the facilitating factors and barriers in performing regular exercise for community dwelling older adults with chronic pain significance of study: chronic pain is a significant issue affecting both physical well-being and socioeconomic aspects across different age groups. among older adults, physical inactivity is common, especially among those experiencing chronic pain. however, regular physical exercise offers numerous health benefits for the musculoskeletal, cardiovascular, and central nervous systems. this project aims to explore the exercise habits and preferences of community-dwelling older adults with chronic pain. by identifying facilitating factors and barriers related to exercise, we can develop tailored exercise programs. these programs will promote healthier habits, allowing older adults to continue living independently in their communities and potentially delaying the need for long-term care facilities.


Eligibility criteria:
inclusion criteria: * aged 60 or above * scored \&gt;6 in the abbreviated mental test * can understand cantonese * have a history of non-cancer pain in the past 6 months exclusion criteria: * have a serious organic disease or malignant tumour * have a mental disorder diagnosed by neurologists or psychiatrists * have further medical/surgical treatment in two months or experienced drug addiction
evaluation of cutaneous and circulating inflammatory biomarkers in hidradenitis suppurativa and atopic dermatitis

Conditions: Hidradenitis Suppurativa; Dermatitis, Atopic

Summary: this non-intervention study will identify the biomarker profiles in hidradenitis suppurativa (hs) and atopic dermatitis (ad) (as a comparator) that would have the most utility in interventional studies evaluating efficacy during therapeutic intervention. study data will also be used to correlate cellular/molecular changes in blood (cells and serum), and tissue, with clinical/histopathological phenotypes.

this study is an exploratory correlative study in subjects with hs or ad. blood samples and skin biopsies will be collected from all subjects and used to assess the following: cutaneous and circulating inflammatory biomarkers and irak4 target levels in primary samples, correlations between cutaneous and circulating inflammatory biomarkers and disease severity, effects of irak4 degradation on irak4 levels and downstream inflammatory biomarkers in ex vivo-treated whole blood from patients. de-identified routine clinical data that is collected will be correlated with the research findings.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. active hs or ad disease, diagnosed by pi 3. patients with mild (hs only), moderate, or severe disease using the hs-pga or pga assessment. 4. must sign an informed consent form (icf) indicating that he or she understands the purpose of and procedures required for the study, and is willing to participate in the study. exclusion criteria: 1. patient is currently on a biologic or other immunosuppressive treatment for hs or ad. 2. use of biologic treatment for hs or ad within 3 months or 5 half-lives, whichever is longer 3. use of non-biologic immunosuppressive treatment (eg. cyclosporin) in the last 4 weeks.

Keywords: irak4
does conscious connected breathwork reduce symptoms of anxiety?

Conditions: Anxiety

Summary: the goal of this clinical trial is to test whether conscious connected breathwork reduces symptoms of anxiety in people with mild to severe anxiety symptoms, as measured by the zung self rating anxiety scale. the main questions aims to answer: 1. does conscious connected breathwork reduce symptoms of anxiety? 2. does an increased frequency of self-practice lead to even greater reductions of anxiety symptoms. there is a comparison group: researchers will compare whether people doing the breathwork to see if \[insert effects\]. participants will participate in 1, 90 minute breath workshop per week for 6 weeks. these sessions will be held on zoom by 2 facilitators. participants will also be given a 10 minute recording of a guided conscious connected breathwork session that they will be encouraged to complete daily.


Eligibility criteria:
inclusion criteria: - scores of 35 or higher on the zung self-rating anxiety scale exclusion criteria: * anyone having completed more than 4 sessions of conscious connected breathwork * anyone who has recently (within 1 year) started anti-depressant medication or psychotherapy * anyone with a history of panic disorder, psychosis, angina, pregnant, seizure disorder, glaucoma

Keywords: anxiety
pancreatic cancer molecular sub-classification using endoscopic ultrasound tissue core biopsy samples

Conditions: Pancreas Cancer

Summary: this study evaluated the feasibility and reliability of pdac molecular subtyping on tissue core biopsies samples acquired under eus guidance. moreover, this study will assess the impact of molecular subtypes assessed on eus-fnb samples in patients with resectable and unresectable (locally advanced, advanced, and metastatic) pdac undergoing chemotherapy on treatment response and survival and the utility in monitoring disease response to therapy and early occurrence of disease relapse using the taqman rna assay in serum

pdac patients are categorised as resectable, borderline resectable, locally advanced, metastatic and recurrent. substantial neoplastic tissue is only available for the resectable group. this is unfortunate as the other groups are those that would benefit the most from molecular characterization and identification of markers, which may be predictive and/or provide therapeutic stratification. for these categories of patients, only fine needle aspiration or small biopsies could be obtained until now. however, the introduction of new needles, specifically designed to acquire larger high quality biopsy samples under endoscopic ultrasound (eus), has now made it possible to test prognostic, predictive and therapeutic stratification markers. however, the applicability of eus-fine needle biopsy (eus-fnb) samples for this purpose has yet to be clinically validated. the working hypothesis of this proposal is that the molecular sub-classification of pdac on eus-fnb tissue samples could be applied for prognostic stratification and therapeutic decision strategies in both resectable and unresectable patients using dna and rna biomarkers.

Eligibility criteria:
inclusion criteria: * patients referred to eus with fnb in the suspect of pancreatic cancer * availability of biopsies obtained during eus-fnb * histological diagnosis of pancreatic ductal adenocarcinoma of any stage * age \>18 and \<80 years * willing to be followed up at the fondazione policlinico a. gemelli university hospital * able to sign informed consent exclusion criteria: * histological diagnoses other than pancreatic ductal adenocarcinoma * pregnancy or lactation * unable to sigh informed consent

Keywords: pancreatic cancer eus molecular subtyping personalized medicine
effect of sarcopenic obesity on weight loss outcomes and quality of life after laparoscopic sleeve gastrectomy

Conditions: Sarcopenic Obesity; Body Composition

Summary: the purpose of this study is to assess the impact of sarcopenic obesity (so) on weight loss outcomes and improvement of quality of life after laparoscopic sleeve gastrectomy.

sarcopenic obesity is a state in which a lack of muscle mass and strength coexists with an increase in fat mass, and it may affect the health outcome of people with obesity after laparoscopic sleeve gastrectomy (lsg).no studies have reported differences in weight loss outcomes between patients with so and those with non-sarcopenic obesity (nso) after lsg. therefore, this study aimed to systematically evaluate the differences in weight loss and quality of life (qol) evaluation between patients with so and nso after lsg and provide high-level evidence-based medical evidence for the impact of so on weight loss in the obese population and refinement of follow-up strategies.

Eligibility criteria:
inclusion criteria: * obese patients who met the indications for lsg and were followed up regularly as planned after surgery. exclusion criteria: 1. incomplete critical clinical data; 2. incomplete imaging data; 3. insufficient follow-up data.

Keywords: laparoscopic sleeve gastrectomy weight loss sarcopenic obesity fat-free mass quality of life
car-t cell immunotherapy for gd2 positive glioma patients

Conditions: Glioma of Brain; CAR-T Cell Immunotherapy

Summary: the purpose of this study is to evaluate the safety and effectiveness of car-t cell immunotherapy in treating with gd2 positive glioma patients.

chimeric antigen receptor (car) is a recombinant receptor with both antigen-binding and t cell activating functions. chimeric antigen receptor t cell immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.this study design a novel specific chimeric antigen receptor aiming at gd2 antigen.after car-t cell infusion,at periodic intervals, the investigators will evaluate clinical symptoms improved conditions of this disease.through this study,the investigators will evaluate the safty and effectiveness of car-t cell immunotherapy in treating with gd2 positive glioma patients.

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies after cancer recurrence * body tumor 1-6, the maximum tumor length \< 2 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: car-t cell immunotherapy gd2 glioma
clinical study of a novel hemolysis point of care test at an emergency department.

Conditions: Hemolysis; Blood Specimen Collection

Summary: this study aims to investigate the outcome of hemolysis frequency when a hemolysis point of care test is introduced in an emergency department.

in a blood sample process, the preanalytical phase is accountable for a vast majority of laboratory test errors. among preanalytical errors, hemolysis is the most frequent error of sample rejection. recollection of blood from the patient causes extra suffering, increased turn-around-time hence delayed treatment, and unnecessary extra costs for the health care system. here is a novel method for hemolysis point of care detection (h-poct) evaluated. the single use test is attached to the blood sample in direct conjunction to the sampling process. patients will be selected by consecutive selection at the emergency department if blood tests ordered by the physician meet the inclusion criteria. patients will be randomized into one of two groups. all health care professionals participating in this study has attended in a standard education program in operating h-poct. if allocated into the control group, n: 750, nurses and enrolled nurses will perform blood sample according to routine. if allocated into the intervention group, n: 750, nurses and enrolled nurses will perform blood sample according to routine and screen all lithium heparin vacuum tubes. (for one or all of the analyzes: liver status, electrolytes and troponin t.) if the hemolysis point of care test (h-poct) indicate a positive test result the lithium heparin vacuum tube and the attached h-poct will be discarded and a new sample will be collected and screened for hemolysis until the user receives a negative sample that is not hemolyzed. this study takes place in a county hospital with 430 beds and the emergency department treats 59000 patients yearly.

Eligibility criteria:
inclusion criteria: blood sample analysis ordered: * electrolyte * troponin t * alat, asat, alp. exclusion criteria: * incompletely filled tubes * minors (\< 18 years) * patient not fit according to the health care professional assessment

Keywords: hemolysis
novel form of nutritional supplementation in cancer patients

Conditions: Cancer; Malnutrition; Cachexia

Summary: this study evaluates if a novel form of oral nutritional supplement application in the form of gumdrops may serve as an alternative to common sip feeds in cancer patients with high risk for malnutrition. within this context the impact of these two different supplements on general condition, quality of life, muscle function, body composition, appetite and nutrition status are investigated. patients are randomly allocated either to a study group with oral supplementation in the form of sip feed or to a study group receiving gumdrops for 4 weeks. after a washout period of 5-7 days study groups are switched for another 4 week intervention period.


Eligibility criteria:
inclusion criteria: * adult patients with solid and hematological malignancies * bmi \< 20 kg/m² and/or nrs-2002 score ≥ 3 exclusion criteria: * pregnant or nursing women * persons with psychiatric disorders with doubts about legal and cognitive capacity * participation in nutritional intervention trials within the last 4 weeks

Keywords: cancer cachexia malnutrition nutritional supplement sip feed nutritional risk
respiratory and physical therapy in patients with associated pulmonary arterial hypertension (apah) with congenital heart defects

Conditions: Pulmonary Arterial Hypertension; Eisenmenger Syndrome

Summary: the purpose of this study is to investigate the influence of physical training on exercise capacity, quality of life, functional class, oxygen consumption and right ventricular function in patients with severe associated pulmonary arterial hypertension (apah) as part of a congenital heart defect with / without eisenmenger's syndrome


Eligibility criteria:
inclusion criteria: * signed consent form * men and women\> 18 years \<80 years * apah with congenital heart defects with / without eisenmenger syndrome (who functional class ii-iv), invasively diagnosed by right heart and left heart catheterization: mean pulmonary arterial pressure (mpap) ≥ 25 mmhg, with targeted pah medication for at least two months stable before study inclusion (exception: compensated who class ii without vasodilating drug therapy) exclusion criteria: * pregnancy or lactation * change in medication during the last 2 months * severe walking disturbance * uncertain diagnoses * no previous invasively confirmation of ph * acute diseases, infections, fever * serious lung disease with fev1 \<50% or tlc \<70% of target * further exclusion criteria are the following diseases: active myocarditis, unstable angina pectoris, exercise-induced ventricular arrhythmias, recurrent syncope within 4 weeks before study entry
translating neuroprediction into precision medicine via brain priming

Conditions: Autism Spectrum Disorder

Summary: the present study examines the impact of oxytocin (oxt) and pivotal response treatment (prt) on the development of language, social, and play skills in young children with autism spectrum disorder (asd). the purpose of this study is to examine the impact of oxt as an enhancer of response to prt. participants will be randomly assigned to either an intranasal oxt group or a placebo group. neither the research team nor the participants will know or choose which group the participant is assigned to. children in both groups will participate in a 16-week trial of prt. the trial will test the hypothesis that children with lower levels of activity in and functional connectivity among certain prt-response brain regions will benefit more from the administration of oxt vs. placebo as an enhancer to a 16-week trial of prt.

this project investigates the effectiveness of a new intervention approach for autism spectrum disorder (asd) to optimize the effects of an evidence-based behavioral intervention, pivotal response treatment (prt) by attempting to enhance it with oxytocin (oxt). we will integrate fmri, eye tracking, and behavioral outcomes to measure how oxt may create a neural background for individuals with asd to bolster their motivation to interact socially and facilitate their biological preparedness for learning social communication skills during behavioral treatments.

Eligibility criteria:
inclusion criteria: 1. fit the age requirement: age 5-9 2. have been diagnosed previously with an asd and meet criteria for asd when characterized by research team 3. be in good medical health 4. be cooperative with testing 5. speak english in the family 6. successfully complete an fmri scan 7. full-scale intelligence quotient (iq)\>70 exclusion criteria: 1. any metal or electromagnetic implants, including: 1. cardiac pacemaker 2. defibrillator 3. artificial heart valve 4. aneurysm clip 5. cochlear implants 6. shrapnel 7. neurostimulators 8. history of metal fragments in eyes or skin 2. significant hearing loss or other severe sensory impairment 3. a fragile health status. 4. current use of prescription psychotropic medications that may affect cognitive processes under study. 5. a history of significant head trauma or serious brain or psychiatric illness
evaluation of artificial intelligence-integrated hearing aids for individuals with hearing loss

Conditions: Hearing Loss; Hearing Loss, Sensorineural

Summary: the goal of this clinical trial will be to evaluate the efficacy of artificial intelligence-integrated hearing aids in individuals with hearing loss. the main questions to answer are: 1. how effective is an artificial intelligence integrated hearing aid in improving speech perception in noise. 2. how does an artificial intelligence integrated hearing aid compare to currently available commercial hearing aids.

hearing loss is a leading cause of disability globally. undertreated hearing loss has been associated with several deleterious sequelae, including social isolation, decreased quality of life, and cognitive decline. for a large portion of individuals with hearing loss, hearing aids remain the intervention of choice for improving communication, decreasing social isolation, and enhancing quality of life. yet, less than 20% of hearing aid candidates choose to use them2. this is partly due to a perceived lack of benefit from hearing aids. individuals who use hearing aids continue to report difficulty with speech perception in noisy environments with multiple speakers, such as parties, restaurants, and other complex auditory settings. the investigators have developed a neural network that runs on-device to achieve real-time target speech hearing in realistic multi-talker environments. using our neural network, the wearer can focus on speech from a target speaker by learning their unique speech cues while ignoring all interfering speech and noise in complex acoustic environments. the wearer is additionally able to use distance to separate sounds from the environment from target sounds to be amplified. finally the wearer is also able to specificy categories of sound that will be amplified in environment. this study will prospectively study a hearing aid implementing these algorithms on individuals with hearing loss. participants will be randomized to utilizing one of two commercial hearing aids vs the experimental device. participants will participate in listening tests in which they must identify the words spoken by a specific voice in multi-talker babble noise. the investigators will measure performance with the primary and secondary outcome measures listed elsewhere.

Eligibility criteria:
inclusion criteria: * minimum age of 18 yo * bilateral sensorineural hearing loss amenable to hearing aids * able to give informed consent * native english speaker * able to wear a standard pair of hearing aids exclusion criteria: * unable to participate in informed consent * use of a cochlear implant * hearing loss not amenable to hearing aid use * conductive hearing loss
a study of rituximab in combination with fludarabine and cyclophosphamide in participants with chronic lymphocytic leukemia and favorable somatic status

Conditions: Lymphocytic Leukemia, Chronic

Summary: this multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with b-cell chronic lymphocytic leukemia (cll) and favorable somatic status.


Eligibility criteria:
inclusion criteria: * diagnosis of previously untreated b-cell cll confirmed immunophenotypically * for participants, age 60-70 years: cumulative illness rating scale (cirs) comorbidity score less than or equal to (\</=) 6 * binet stage b, c or a with progression * life expectancy greater than or equal to (\>/=) 12 months * eastern cooperative oncology group (ecog) performance status (ps) 0-2 * women of child bearing potential and men should agree to use highly reliable contraceptive method throughout the treatment period and within 12 months after treatment completion exclusion criteria: * participants with small-cell lymphoma * participants with auto-immune hemolytic anemia * concomitant malignant disease during enrollment, except basal cell carcinoma of the skin * chemotherapy for concomitant malignant disease given within 12 months prior to study enrollment * participants with richter's syndrome * participants with symptomatic hepatitis b infection * any clinically significant infection that could not be cured prior to enrollment, including human immunodeficiency virus (hiv) infection * creatinine clearance less than (\<) 30 milliliters per minute (ml/min) * participants with congestive heart failure (chf) new york heart association (nyha) iii-iv * participants with liver failure and acute hepatitis of any etiology * any other medical or mental condition which may preclude from receiving the entire course of protocol specified treatment or signing the informed consent * history of an anaphylactic reaction to murine antibodies, proteins, or any other ingredient of rituximab * pregnancy and breast-feeding women